Gene Therapies in Neurology

Sponsored by: GlobalData

Focused on:

  • Gene Therapy
  • Neurology

Date: 25 September

Days to go: 9

Time: 3PM London/10AM New York

A review of developments and trends in gene therapies for neurology indications

Gene therapy is an evolving area in healthcare that promises to revolutionize the treatment landscapes across various therapy areas. In this webinar, the focus will be on neurology indications. Recently approved gene therapies for spinal muscular atrophy have reinvigorated the potential of such therapies to transform patient care.

While various methodologies can be adopted in order to deliver therapeutic benefits of gene therapy including gene augmentation, gene suppression, and gene editing, an important component of gene therapy is whether to use viral or non-viral vectors in order to deliver such therapies to the point of care.

In this webinar Vinie Varkey, Senior Analyst at GlobalData, will present an analysis of the overall gene therapy pipeline that is being developed for various neurology indications with an emphasis on late-stage pipeline products. The session will draw insights from GlobalData’s recently published report, Gene Therapies in Neurology. In addition to pipeline analysis, the session will also focus on trends observed in clinical trials in this area, unmet needs and challenges, as well as partnership strategies adopted by pharmaceutical companies to keep up with developments in the field of gene therapies. Maura Musciacco, Therapy Senior Director at GlobalData, will moderate a Q&A session following the presentation.

Presented by

Vinie Varkey,

Senior Analyst

Her core responsibilities involve providing in-depth analysis, market intelligence and forecasting, and data interpretation in the neurology and ophthalmology pharmaceutical sectors. Prior to her role in the neurology team, she was an analyst with the medical devices team at GlobalData. Prior to joining GlobalData, she worked as business development specialist for a healthcare company. Vinie holds an MSc degree in Biotechnology, Bioprocessing and Business Management from the University of Warwick, UK.

Maura Musciacco,

Senior Director, Neurology & Ophthalmology

Maura Musciacco, MSc, is the Senior Director of Neurology and Ophthalmology at GlobalData in London. She has over a decade of experience in market analysis, business intelligence and providing strategic insight for the pharmaceutical industry. Prior to her current role, she was a Lead Analyst for Company Analysis at Datamonitor Healthcare, where she managed the portfolio and production of the team covering the top 40 pharmaceutical companies, in addition to being the in-house specialist for the orphan drug sector. Previously, she was an Analyst in the Strategy team at Datamonitor Healthcare, where she gained extensive experience writing in-depth reports covering various topics, including mergers and acquisitions, emerging markets, generics, and R&D trends. Maura started her career in market research, where she uncovered needs and trends in several therapeutic markets. She has an MSc in International Health Management from the Imperial College Business School, and a BSc in Molecular Biology from University College London (UCL).

Key Learning Objectives

  • Gain insights on pipeline products for neurology indications by development phase and vector types
  • Learn about clinical trials’ trends including their duration for Phase II and III products
  • Gain insight into unmet needs, challenges for product development, and key company strategies
  • Learn about payer perspectives on gene therapies including challenges and strategies to tackle them


  • Managers/Senior Managers/Associate Directors/Directors of Market Research
  • Business Insights
  • Market Intelligence
  • Strategic Insights
  • Forecasting
  • Pipeline Management
  • Competitive Strategy
  • Customer Insights
  • Heads of Research and Development
  • Heads of Product Planning and Marketing
  • Brand Managers